Table 5.
Prolonged and point prevalence confirmed abstinence from smoking at follow-up in patients using nortriptyline plus nicotine replacement therapy or placebo plus nicotine replacement therapy. Values are numbers (percentages) of participants unless stated otherwise
| Variable | Intention to treat analysis | Per protocol analysis | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Nortriptyline group (n=445) | Placebo group (n=456) | Difference % (95% CI) | Relative risk (95% CI) | Nortriptyline group (n=337) | Placebo group (n=325) | Difference % (95% CI) | Relative risk (95% CI) | ||
| Prolonged abstinence: | |||||||||
| 4 weeks | 220 (49.4) | 211 (46.3) | 3.2 (−3.4 to 9.7) | 1.07 (0.92 to 1.22) | 197 (58.5) | 186 (56.0) | 1.2 (−6.3 to 8.8) | 1.04 (0.91 to 1.19) | |
| 6 months | 72 (16.2) | 55 (12.1) | 4.1 (−0.4 to 8.7) | 1.34 (0.97 to 1.86) | 67 (19.9) | 46 (14.2) | 5.7 (0.0 to 11.4) | 1.40 (1.00 to 1.98) | |
| 12 months | 49 (11.0) | 40 (8.8) | 2.2 (−1.7 to 6.1) | 1.26 (0.84 to 1.87) | 44 (13.1) | 33 (10.2) | 2.9 (−2.0 to 7.8) | 1.29 (0.84 to 1.97) | |
| Point prevalence abstinence: | |||||||||
| 4 weeks | 283 (63.6) | 270 (59.2) | 4.4 (−2.0 to 10.7) | 1.07 (0.97 to 1.19) | 247 (73.3) | 224 (68.9) | 4.4 (−2.5 to 11.3) | 1.06 (0.96 to 1.17) | |
| 6 months | 75 (16.9) | 57 (12.5) | 4.4 (−0.3 to 9.0) | 1.35 (0.98 to 1.85) | 69 (20.5) | 48 (14.8) | 5.7 (−0.1 to 11.5) | 1.39 (0.99 to 1.94) | |
| 12 months | 59 (13.3) | 48 (10.5) | 2.7 (−1.5 to 7.0) | 1.26 (0.88 to 1.80) | 52 (15.4) | 40 (12.3) | 3.1 (−2.1 to 8.4) | 1.25 (0.85 to 1.84) | |